FDA Grants Tagrisso® Priority Review for Unresectable Stage III EGFR-Mutated Lung Cancer
AstraZeneca has filed and received Priority Review status in the United States for TAGRISSO® (osimertinib) for treating adult patients...
FDA Approves Almirall’s Revolutionary New Klisyri® for Expanded Treatment of Skin Cancer
The U.S. Food and Drug Administration (FDA) has approved Almirall’s expanded use of Klisyri for actinic keratosis (AK) treatment....
AstraZeneca’s Investment Powers Nucleus Radiopharma’s Series A Extension
Nucleus RadioPharma has expanded its capabilities with a Series A investment extension and the appointment of Dr. Tyrell Rivers...
Twist Bioscience Discovery in Antibody Engineering
Twist Bioscience has unveiled TB206-001, an antibody antagonist targeting the adenosine A2A receptor (A2AR). This discovery represents a significant...
Gilead Announces Breakthrough HDV Treatment Data in New England Journal of Medicine
A study published in the New England Journal of Medicine and presented at the European Association for the Study...
ICH Shifts Strategy to Incorporate The Patient’s Persperctive
The ICH Townhall at the 2024 DIA Europe conference featured insightful discussions on the critical role of the International...
Reducing Reliance on Animal Models: Charles River’s Virtual Control Groups
Charles River Laboratories and Sanofi have partnered to explore the use of Virtual Control Groups (VCGs) in nonclinical toxicology....
Elemind Introduces Sleep Solution, Empowering Sleep Control
Elemind, a neurotech wellness company, has introduced a revolutionary headband that harnesses advanced neurotechnology to improve sleep quality. The...
Be Bio: FDA Grants New Designation for Novel Medicine – Hemophilia B Breakthrough
Be Biopharma (Be Bio) announced that the FDA has granted Orphan Drug Designation to BE-101, an engineered B Cell...
Breyanzi: Remarkable Outcomes in B-Cell Malignancies Revealed
Long-term follow-up data from the TRANSFORM trial reveals that Breyanzi, a chimeric antigen receptor T-cell (CAR T) therapy, continues...